Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | EIF4E | P06730 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762159 | 0.89 | KDM4E (0.42) | MRGPRX4EIF4E | |
| SCHEMBL3747380 | 0.84 | CBFB (0.35) | MRGPRX4FFAR4FFAR1RIPK1SCN9A | |
| SCHEMBL3752315 | 0.83 | MPL (0.40) | RIPK1SCN9ADHODH | |
| SCHEMBL3755130 | 0.83 | KMO (0.44) | EIF4EDHODH | |
| SCHEMBL3754181 | 0.82 | PLG (0.43) | EIF4EAKR1C2 | |
| SCHEMBL3750445 | 0.81 | EIF4E (0.43) | EIF4ESCN9ADHODH | |
| SCHEMBL3758381 | 0.81 | MRGPRX4 (0.42) | MRGPRX4EIF4ESCN9A | |
| SCHEMBL3753505 | 0.78 | ALDH1A1 (0.43) | EIF4EDHODH | |
| SCHEMBL3758001 | 0.78 | PLAU (0.43) | EIF4EDHODH | |
| SCHEMBL3747340 | 0.77 | KDM4E (0.44) | MRGPRX4EIF4ESCN9APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | MRGPRX4 4532/4885FFAR4 279/4885EIF4E 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.